| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 32 | 2025 | 2498 | 1.900 |
Why?
|
| Receptor, ErbB-2 | 16 | 2025 | 514 | 1.370 |
Why?
|
| Physical and Rehabilitation Medicine | 2 | 2022 | 33 | 0.890 |
Why?
|
| Lymphedema | 2 | 2023 | 19 | 0.840 |
Why?
|
| Head and Neck Neoplasms | 3 | 2024 | 490 | 0.770 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2019 | 4 | 0.630 |
Why?
|
| Phyllodes Tumor | 2 | 2013 | 11 | 0.530 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2025 | 717 | 0.530 |
Why?
|
| Quinazolines | 11 | 2023 | 174 | 0.520 |
Why?
|
| Trastuzumab | 11 | 2025 | 134 | 0.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 1214 | 0.510 |
Why?
|
| Neoadjuvant Therapy | 9 | 2023 | 337 | 0.490 |
Why?
|
| Receptors, Estrogen | 11 | 2022 | 797 | 0.440 |
Why?
|
| Neoplasms | 5 | 2023 | 2771 | 0.440 |
Why?
|
| Ultrasonography, Mammary | 1 | 2013 | 28 | 0.430 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 28 | 0.420 |
Why?
|
| Biomarkers, Tumor | 9 | 2023 | 1484 | 0.410 |
Why?
|
| Osteosarcoma | 1 | 2013 | 253 | 0.350 |
Why?
|
| Molecular Targeted Therapy | 7 | 2025 | 354 | 0.350 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2016 | 256 | 0.340 |
Why?
|
| Ki-67 Antigen | 3 | 2022 | 113 | 0.330 |
Why?
|
| Tamoxifen | 5 | 2016 | 363 | 0.320 |
Why?
|
| Immunohistochemistry | 4 | 2022 | 1690 | 0.270 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2017 | 259 | 0.230 |
Why?
|
| STAT5 Transcription Factor | 2 | 2022 | 89 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2018 | 882 | 0.220 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 1660 | 0.220 |
Why?
|
| Female | 37 | 2025 | 66485 | 0.210 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 111 | 0.210 |
Why?
|
| Humans | 42 | 2025 | 124596 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2020 | 505 | 0.200 |
Why?
|
| Deglutition Disorders | 1 | 2024 | 130 | 0.190 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 74 | 0.190 |
Why?
|
| Human Trafficking | 1 | 2022 | 42 | 0.190 |
Why?
|
| Quinolines | 1 | 2022 | 98 | 0.190 |
Why?
|
| Cell Line, Tumor | 8 | 2018 | 3337 | 0.190 |
Why?
|
| Genes, erbB-2 | 3 | 2011 | 37 | 0.180 |
Why?
|
| Gene Editing | 1 | 2023 | 187 | 0.180 |
Why?
|
| Physical Therapy Modalities | 1 | 2021 | 51 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 4 | 2011 | 1018 | 0.170 |
Why?
|
| Pathology, Clinical | 1 | 2019 | 23 | 0.160 |
Why?
|
| Gene Expression | 3 | 2020 | 1561 | 0.160 |
Why?
|
| Signal Transduction | 9 | 2025 | 4501 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 113 | 0.160 |
Why?
|
| Optical Imaging | 1 | 2019 | 65 | 0.150 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 1 | 2018 | 19 | 0.150 |
Why?
|
| Middle Aged | 13 | 2020 | 26714 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 406 | 0.140 |
Why?
|
| Tissue Array Analysis | 2 | 2015 | 137 | 0.140 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2014 | 100 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2017 | 1893 | 0.130 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 48 | 0.130 |
Why?
|
| Estradiol | 2 | 2016 | 535 | 0.130 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 555 | 0.130 |
Why?
|
| Treatment Outcome | 8 | 2023 | 12322 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 469 | 0.130 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 105 | 0.130 |
Why?
|
| Adult | 14 | 2022 | 29438 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2016 | 208 | 0.120 |
Why?
|
| Quality of Life | 2 | 2024 | 1916 | 0.120 |
Why?
|
| Mice | 13 | 2023 | 17630 | 0.120 |
Why?
|
| Mice, Nude | 5 | 2018 | 707 | 0.120 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2018 | 235 | 0.120 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 1882 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 71 | 0.110 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 107 | 0.110 |
Why?
|
| Granulomatous Mastitis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Hospitals, County | 1 | 2013 | 23 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 61 | 0.110 |
Why?
|
| Disease Models, Animal | 4 | 2023 | 4350 | 0.110 |
Why?
|
| Hospitals, Urban | 1 | 2013 | 99 | 0.100 |
Why?
|
| Animals | 15 | 2023 | 34072 | 0.100 |
Why?
|
| Transcriptome | 2 | 2016 | 952 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 468 | 0.100 |
Why?
|
| Sirolimus | 1 | 2014 | 222 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2025 | 529 | 0.100 |
Why?
|
| Fibroadenoma | 1 | 2012 | 9 | 0.100 |
Why?
|
| ErbB Receptors | 3 | 2011 | 281 | 0.100 |
Why?
|
| Oncogenes | 2 | 2013 | 167 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2022 | 616 | 0.100 |
Why?
|
| Atrioventricular Node | 1 | 2011 | 18 | 0.090 |
Why?
|
| Death, Sudden | 1 | 2011 | 45 | 0.090 |
Why?
|
| Lymphoma, T-Cell | 1 | 2011 | 64 | 0.090 |
Why?
|
| Heart Neoplasms | 1 | 2011 | 101 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 665 | 0.080 |
Why?
|
| Fibroblasts | 1 | 2014 | 882 | 0.080 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2009 | 78 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 4795 | 0.080 |
Why?
|
| Models, Biological | 1 | 2014 | 1459 | 0.080 |
Why?
|
| Prognosis | 4 | 2020 | 4626 | 0.080 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2008 | 88 | 0.070 |
Why?
|
| Lentivirus | 1 | 2008 | 82 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1248 | 0.070 |
Why?
|
| Smad5 Protein | 1 | 2007 | 22 | 0.070 |
Why?
|
| Smad1 Protein | 1 | 2007 | 22 | 0.070 |
Why?
|
| Exercise | 2 | 2024 | 813 | 0.070 |
Why?
|
| Breast | 2 | 2022 | 214 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2009 | 676 | 0.070 |
Why?
|
| Adnexa Uteri | 1 | 2006 | 9 | 0.070 |
Why?
|
| Jejunal Diseases | 1 | 2006 | 15 | 0.070 |
Why?
|
| CA-125 Antigen | 1 | 2006 | 15 | 0.070 |
Why?
|
| Aged | 8 | 2020 | 19703 | 0.070 |
Why?
|
| Ovarian Diseases | 1 | 2006 | 28 | 0.070 |
Why?
|
| Antigens, Differentiation | 1 | 2006 | 61 | 0.060 |
Why?
|
| Fistula | 1 | 2006 | 49 | 0.060 |
Why?
|
| Antibodies, Blocking | 1 | 2006 | 61 | 0.060 |
Why?
|
| Testis | 1 | 2007 | 407 | 0.060 |
Why?
|
| Mutation | 5 | 2018 | 5825 | 0.060 |
Why?
|
| Ovary | 1 | 2007 | 379 | 0.060 |
Why?
|
| MCF-7 Cells | 2 | 2016 | 222 | 0.060 |
Why?
|
| Biopsy | 2 | 2022 | 1237 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2020 | 1496 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2008 | 940 | 0.060 |
Why?
|
| Cell Survival | 2 | 2018 | 806 | 0.060 |
Why?
|
| Mammary Glands, Animal | 2 | 2022 | 481 | 0.050 |
Why?
|
| Pelvic Neoplasms | 1 | 2003 | 21 | 0.050 |
Why?
|
| Recombinational DNA Repair | 1 | 2023 | 16 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 87 | 0.050 |
Why?
|
| Receptors, Progesterone | 3 | 2015 | 878 | 0.050 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 79 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 6533 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2876 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2024 | 153 | 0.050 |
Why?
|
| Survivors | 1 | 2023 | 325 | 0.050 |
Why?
|
| CRISPR-Cas Systems | 1 | 2023 | 253 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 361 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 414 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 71 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 68 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2022 | 579 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2017 | 2285 | 0.040 |
Why?
|
| Cell Division | 2 | 2013 | 777 | 0.040 |
Why?
|
| Melanoma | 1 | 2006 | 834 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 1327 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 808 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 299 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2022 | 909 | 0.040 |
Why?
|
| Male | 4 | 2019 | 61192 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2013 | 1177 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 127 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 607 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 228 | 0.030 |
Why?
|
| Apoptosis | 2 | 2013 | 1789 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 1702 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 173 | 0.030 |
Why?
|
| HIV Infections | 1 | 2006 | 1892 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 171 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 660 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1615 | 0.030 |
Why?
|
| Doxycycline | 1 | 2014 | 117 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2014 | 206 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 355 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2013 | 3729 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 285 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 337 | 0.030 |
Why?
|
| Mammography | 1 | 2013 | 114 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 6292 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 146 | 0.020 |
Why?
|
| Steroids | 1 | 2013 | 202 | 0.020 |
Why?
|
| Triazoles | 1 | 2013 | 137 | 0.020 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2012 | 30 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2008 | 3038 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2013 | 568 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 430 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 486 | 0.020 |
Why?
|
| Forensic Pathology | 1 | 2011 | 7 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 721 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 1645 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2013 | 331 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 208 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 240 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5145 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 862 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 374 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 50 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 354 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 1420 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 617 | 0.020 |
Why?
|
| Keratin-9 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Alpharetrovirus | 1 | 2008 | 5 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 928 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2008 | 92 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 186 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 257 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2008 | 106 | 0.020 |
Why?
|
| Smad8 Protein | 1 | 2007 | 6 | 0.020 |
Why?
|
| Sertoli Cell Tumor | 1 | 2007 | 8 | 0.020 |
Why?
|
| Granulosa Cell Tumor | 1 | 2007 | 40 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 869 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 2047 | 0.020 |
Why?
|
| HIV | 1 | 2008 | 180 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1032 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 121 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 254 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 2007 | 132 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 2154 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2006 | 53 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 3063 | 0.020 |
Why?
|
| Ascites | 1 | 2006 | 88 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2006 | 183 | 0.020 |
Why?
|
| Myocardium | 1 | 2011 | 997 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 1350 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2006 | 73 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 797 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 9014 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2006 | 227 | 0.020 |
Why?
|
| Fertility | 1 | 2007 | 257 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2006 | 172 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2006 | 201 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2013 | 16314 | 0.010 |
Why?
|
| Survival Rate | 1 | 2009 | 2044 | 0.010 |
Why?
|
| Estrogens | 1 | 2007 | 513 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2007 | 790 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2006 | 420 | 0.010 |
Why?
|
| Research Design | 1 | 2008 | 691 | 0.010 |
Why?
|
| Obesity, Morbid | 1 | 2006 | 187 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 4256 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 2392 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2003 | 299 | 0.010 |
Why?
|
| Child | 1 | 2022 | 24375 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 1140 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2426 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 419 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 7179 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 3441 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 2091 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2006 | 1706 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 1312 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 10270 | 0.010 |
Why?
|